Elevance Health Inc.

(New York Stock Exchange)
Back to all articles
Somewhat Bullish +50

Elevance Health (ELV) Stock Stays Undervalued Despite Its 37% Run - simplywall.st

AI-generated analysis

πŸ“ˆ Elevance Health (ELV) has returned 37.5% over the last 12 months, yet valuation checks still classify it as undervalued.

πŸ“Š The stock trades at a P/E of 18.1x, well below the healthcare industry average of 25.3x and peer group average of 27.8x.

🎯 Analysts estimate a fair P/E multiple of 34.8x for Elevance Health, suggesting a significant undervaluation gap.

πŸ‘€ Dr. Patrick Fox has been appointed to lead Carelon Behavioral Services to support profitable growth expectations.

πŸ€– The company is expanding the use of AI in its business to boost efficiency and reduce operational costs.

⚠️ Elevated costs in government-backed plans pose a risk that could compress margins despite operational improvements.

πŸ₯ Greater reliance on value-based care models presents a potential headwind for Elevance Health's profitability.

πŸ’° The company operates with an excellent balance sheet and currently pays a dividend to shareholders.

Bullish Signals
  • Elevance Health trades at a P/E of 18.1x, which is materially lower than the healthcare industry average of 25.3x and peer group average of 27.8x.
  • Analysts estimate a fair P/E multiple of 34.8x for Elevance Health, indicating the current market price implies a sizeable undervaluation gap.
  • The appointment of Dr. Patrick Fox to lead Carelon Behavioral Services is expected to support expectations for profitable growth.
  • Technology investments in analytics, digitization, and AI are boosting efficiency and reducing costs across Elevance Health's operations.
  • Elevance Health operates with an excellent balance sheet and pays a dividend, providing financial stability.
Risk Factors
  • Elevated costs in government-backed plans could compress margins despite the company's operational improvements and diversification strategies.
  • Greater reliance on value-based care models presents a risk that may hinder Elevance Health's ability to maintain high profit margins.
Full Analysis
Elevance Health (ELV) has gained 37.5% over the past 12 months, yet valuation metrics suggest the stock remains undervalued relative to its fundamentals and peers. The company currently trades at a P/E ratio of 18.1x, which is significantly lower than the wider healthcare industry average of 25.3x and a peer group average of 27.8x. Analysts estimate a fair P/E multiple for Elevance Health to be approximately 34.8x, indicating a substantial gap between current market pricing and implied value. This discount persists despite recent strategic initiatives, including the appointment of Dr. Patrick Fox to lead Carelon Behavioral Services and increased investment in AI-driven efficiencies. The core investment thesis hinges on whether Elevance Health can successfully manage rising costs associated with government-backed plans and value-based care models. If the company can maintain margin stability through its technology investments and operational improvements, the current valuation may appear conservative. Conversely, if these external cost pressures outweigh internal efficiencies, the multiple could be justified as fair rather than cheap.